Home Stock

Stock Research: Cosmo Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Cosmo Pharmaceuticals

SWX:COPN NL0011832936
50
  • Value
    28
  • Growth
    78
  • Safety
    Safety
    58
  • Combined
    66
  • Sentiment
    37
  • 360° View
    360° View
    50
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on gastrointestinal diseases, dermatology, and healthtech. It operates in the pharmaceutical industry and its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, GI Genius, Eleview, Aemcolo, Methylene Blue MMX, and Winlevi. In the last fiscal year, the company had a market cap of $1,357 million, profits of $229 million, and revenue of $276 million, with 322 employees.

more

ANALYSIS: With an Obermatt 360° View of 50 (better than 50% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cosmo Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Cosmo Pharmaceuticals. The consolidated Growth Rank has a good rank of 78, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 78% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 58 which means that the company has a financing structure that is safer than 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 28 which means that the share price of Cosmo Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 72% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 37, which means that professional investors are more pessimistic about the stock than for 63% of alternative investment opportunities. ...read more

more
Strongest Rank Market Pulse
Weakest Rank Analyst Opinions
Country Ireland
Industry Pharmaceuticals
Size Small
Website cosmopharma.com
Index
SPI
Cosmo Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
28 34 57 32
Growth
78 45 77 33
Safety
Safety
58 54 30 47
Sentiment
37 94 100 74
360° View
360° View
50 67 94 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 87 100 95
Opinions Change
50 50 83 50
Pro Holdings
n/a 96 80 60
Market Pulse
1 57 53 21
Sentiment
37 94 100 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
28 34 57 32
Growth
78 45 77 33
Safety Safety
58 54 30 47
Combined
66 43 62 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
16 13 18 7
Price vs. Earnings (P/E)
1 75 46 5
Price vs. Book (P/B)
41 59 67 85
Dividend Yield
73 1 70 57
Value
28 34 57 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
93 8 88 8
Profit Growth
31 100 98 100
Capital Growth
44 33 15 44
Stock Returns
92 45 38 22
Growth
78 45 77 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
93 95 46 39
Refinancing
56 43 39 78
Liquidity
6 24 29 19
Safety Safety
58 54 30 47

Similar Stocks

Discover high‑ranked alternatives to Cosmo Pharmaceuticals and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Glenveagh Properties

ISE:GVR
Country: Ireland
Industry: Homebuilding
Size: Medium
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews